BerGenBio
Be the first to follow this company
BerGenBio is a Norwegian oncology company. The company conducts research and development of inhibitory drugs for the treatment of aggressive cancers. The company has developed a number of products whose composition intends to block the protein AXL, a protein positively related to the spread of cancer cells. The company was founded in 2007 and is headquartered in Bergen.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
Oslo Børs
BGBIO
Daily low / high price
-
Market cap
-
Turnover
-
Volume
-
Financial calendar
General meeting
23.05.2024
Interim report
29.05.2024
Interim report
21.08.2024
Interim report
13.11.2024
Annual report
19.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Meteva AS | 26.2 % | 26.2 % |
Investinor Direkte AS | 4.1 % | 4.1 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
BerGenBio ASA: New share capital registered
BerGenBio ASA: Resolution to increase the share capital for settlement of underwriting commission
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools